

**Urteste S.A.**  
**ul. Starodworska 1**  
**80-137 Gdańsk**

**7.11. 2025**

**Current report no. 17/2025**  
**dated November 7, 2025**

Subject: Conclusion of two investment agreements concerning the recapitalization of the Company.

Legal basis: Art. 17(1) MAR – confidential information.

The Management Board of Urteste S.A. with its registered office in Gdańsk (the "Company," the "Issuer") announces that on November 7, 2025, the Issuer concluded two investment agreements concerning the recapitalization of the Company (the "Agreements," each individually referred to as the "Agreement") with Polish private investors who undertook to acquire newly issued shares of the Company, i.e.:

a) the first investor, who will acquire 64,300 newly issued shares of the Company at an issue price of PLN 38.38 per share, i.e. for a total amount of PLN 2,467,834.00 (in words: two million four hundred sixty-seven thousand eight hundred thirty-four zlotys 00/100);

b) with the second investor, who will acquire 52,111 newly issued shares of the Company at an issue price of PLN 38.38 per share, i.e. for a total amount of PLN 2,000,020.18 (in words: two million twenty zlotys 18/100).

The concluded investment agreements concern a total of 116,411 shares for a total amount of PLN 4,467,854.18 (four million four hundred sixty-seven thousand eight hundred fifty-four zlotys 18/100).

The investment agreements were concluded subject to the condition precedent of the Company's General Meeting adopting a resolution on increasing the Company's share capital by issuing series G ordinary bearer shares, excluding the preemptive rights of existing shareholders, amending the Company's Articles of Association, dematerializing series G shares, and applying for the admission and introduction of series G shares to trading on the regulated market operated by the Warsaw Stock Exchange. (the "Issue Resolution") by December 10, 2025.

The Company notes that the agreement with the second investor contains a provision stipulating that the investor has the right to withdraw from the Agreement, which the Investor may exercise by the date of adoption of the Issue Resolution.

The capital raised in the planned share issue will enable the Company to conduct full operations until the interim results of the European clinical trial in the Panuri project are obtained. In the opinion of the Management Board, obtaining these results will significantly increase the likelihood of concluding a partnership transaction regarding the Panuri test.



The Issuer will soon convene a General Meeting of Shareholders to consider and adopt a resolution on the issue of 116,411 shares for a total amount of PLN 4,467,854.18 (four million four hundred sixty-seven thousand eight hundred fifty-four zlotys 18/100).

